Malaria elimination or eradication efforts are underway and strategies such as new drugs, vaccines and vector control techniques, are being implemented to reduce and even eliminate the health burden of malaria. Anti-malarial drug treatment is an essential part of all malaria control programs, and drug resistance is a major factor that may undermine these efforts to control malaria. To prevent or limit the effect of emerging drug resistance it will be critical to monitor the effectiveness of available anti-malarial drugs, as well as evaluate new safe and economical drugs that are active against drug resistant parasites. Successful eradication of malaria will require careful assessment of current levels of drug resistance and clinical responses to drug treatments, as well as development of simple methods to assess drug resistance and response levels more broadly across malaria endemic regions. This will require the development of tools to monitor drug responses and detect changes in the parasite population in response to current or future drug applications. Prolonged application of incompletely effective chemotherapeutic treatments thus leads to the spread and fixation of drug resistance alleles in areas where malaria is endemic. New drugs or new combinations of drugs, including Artemisinin Combination Therapies (ACTs) and use of Intermittent Preventive Treatment in pregnancy (IPTp), have been introduced to reduce and perhaps ultimately eliminate the disease burden of malaria. In this proposal we will assess the current level of drug resistance to ACTs and the effectiveness of IPTp treatment in four sentinel sites in West Africa. We will characterize the drug responses of parasites currently causing malaria infection in these sites, and use population genetic approaches to discover genetic markers associated with these resistant parasites. From these data we will identify novel molecular markers that will be validated and tested for their role in drug resistance and their utility for identification of drug resistant parasites in patients. Development of simple and reliable genotyping assays for these markers will then enable clinicians and researchers to identify and track parasites that are likely to fail drug treatment and compromise malaria control strategies.
Drug resistance is a major factor that can undermine malaria control programs. Understanding the consequnces of drug pressure on the parasite population structure including the selection of genetic variants that can evade drug pressure will be essential for any successful malaria elimination or eradication effort. Simple and inexpensive assays to monitor the effects of drug pressure on malaria parasites will be critical to ensure the success of malaria control programs.
|Talundzic, Eldin; Ndiaye, Yaye D; Deme, Awa B et al. (2017) Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing. Antimicrob Agents Chemother 61:|
|Ndiaye, Yaye Dié; Diédhiou, Cyrille K; Bei, Amy K et al. (2017) High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations. Malar J 16:153|
|Mbaye, Aminata; Gaye, Amy; Dieye, Baba et al. (2017) Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal. Malar J 16:250|
|Koita, Ousmane A; Sangaré, Lansana; Miller, Haiyan D et al. (2017) AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis 17:1266-1275|
|Koita, Ousmane A; Murphy, Robert L; Fongoro, Saharé et al. (2016) Clinical Research and the Training of Host Country Investigators: Essential Health Priorities for Disease-Endemic Regions. Am J Trop Med Hyg 94:253-7|
|Dieye, Baba; Affara, Muna; Sangare, Lassana et al. (2016) West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia. Am J Trop Med Hyg 95:1054-1060|
|Mbaye, Aminata; Dieye, Baba; Ndiaye, Yaye D et al. (2016) Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Malar J 15:433|
|Wilson, Mark L; Krogstad, Donald J; Arinaitwe, Emmanuel et al. (2015) Urban Malaria: Understanding its Epidemiology, Ecology, and Transmission Across Seven Diverse ICEMR Network Sites. Am J Trop Med Hyg 93:110-23|
|Colborn, James M; Ylöstalo, Joni H; Koita, Ousmane A et al. (2015) Human Gene Expression in Uncomplicated Plasmodium falciparum Malaria. J Immunol Res 2015:162639|
|Papa Mze, Nasserdine; Ndiaye, Yaye Die; Diedhiou, Cyrille K et al. (2015) RDTs as a source of DNA to study Plasmodium falciparum drug resistance in isolates from Senegal and the Comoros Islands. Malar J 14:373|
Showing the most recent 10 out of 24 publications